Does not appear to be any update for the sepsis or Covid/Flu A/Flu B space in the Report. That concerns me, as the life sciences update seems to be more geared towards to acquisitions rather than development of new tests.
EDIT: "Cessation and realignment of resources from existing clinical developments (COVID-19, Multiplex, PCT) to assay development, due to regulatory and market conditions."
Ann: Company Update, page-2
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $52.98M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.3¢ | 2.1¢ | $21.26K | 972.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 3457982 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1104891 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
2.1¢ |
Change
-0.001 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.3¢ | 2.1¢ | 552096 | ||
| Last updated 13.47pm 30/04/2024 ? | |||||
| ADO (ASX) Chart |